Aprea Therapeutics, Inc. (APRE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.67. The rating moved from Neutral to Overbought on August 11, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$0.67
• Last changeMoved from Neutral to Overbought on August 11, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Aprea Therapeutics, Inc. (APRE) is a small clinical-stage biotechnology company whose near-term equity value is primarily driven by pipeline milestones, financing events, and partnership activity rather than recurring revenue. Competitive positioning depends on the unique attributes and clinical data for its assets; successful readouts or licensing deals would materially improve prospects, while negative data would be highly punitive. Market perception is muted with limited social/research coverage, but the current constructive risk-on tone in growth sectors could support speculative inflows. Monitor upcoming clinical milestones, cash runway and any partnering or financing announcements closely.

Key factors

• Clinical-stage biotech profile with most value tied to pipeline progress and near-term clinical/regulatory catalysts
• Very limited or no sustainable commercial revenue; valuation driven by binary trial readouts and licensing/partnering prospects
• Small-cap liquidity and market microstructure increase volatility and widen bid/ask spreads
• Sector tailwinds for biologics and CDMO/CRO demand could be a modest positive for partnership interest or M&A optionality
• Macro market tone modestly risk-on for growth names in the short term, which can support speculative biotech flows

Risks

• Clinical trial failures or negative readouts that could cause steep share-price declines
• Short cash runway and need to raise capital, leading to meaningful dilution for existing shareholders
• Regulatory setbacks or unexpected safety issues that delay development timelines
• Highly competitive oncology/biotech landscape with larger peers and better-funded entrants
• Low analyst coverage and limited social sentiment data increase information asymmetry and downside from surprise news

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.